Patents Assigned to Pfizer
  • Publication number: 20040224962
    Abstract: Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
    Type: Application
    Filed: March 3, 2004
    Publication date: November 11, 2004
    Applicant: Pfizer Inc
    Inventors: Jotham W. Coe, Philip A. Iredale, Steven B. Sands
  • Patent number: 6814971
    Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: November 9, 2004
    Assignee: Pfizer Inc.
    Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
  • Patent number: 6814878
    Abstract: A batch process for carrying out a hydrogenation reaction comprises mixing a pyrophoric catalyst with reactants and solvents to form a reaction mixture in a reaction vessel. Hydrogen is added to the reaction vessel. After hydrogenation, the desired hydrogenation product is removed from the reaction vessel and the pyrophoric catalyst-rich material from the reaction vessel is delivered to a pressure filter. Water is added to the pyrophoric catalyst-rich material in the filter and the spent pyrophoric material is removed from the pressure filter in a water wet form.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: November 9, 2004
    Assignee: Pfizer Science and Technology Ireland Limited
    Inventor: William Tully
  • Patent number: 6815424
    Abstract: Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: November 9, 2004
    Assignee: Pfizer Corporation
    Inventors: Brian H. Vickery, Eric J. Benjamin, Cherng-Chyi Fu, Lynda M. Sanders
  • Publication number: 20040219653
    Abstract: The invention is directed generally to the structure of lipid binding proteins, particularly human lipid binding protein (aP2), a protein important in adipocyte function. The invention also relates to the use of a crystal structure of human lipid binding protein or mutants and the interaction with ligands for the design of inhibitors. Furthermore, the invention relates to the structure of ligand binding sites.
    Type: Application
    Filed: April 30, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc
    Inventor: Xiayang Qiu
  • Publication number: 20040219228
    Abstract: An animal model for inflammatory bowel disease is described. The model is based on a mammal not expressing a functional mdr1a gene product, or wherein the mdr1a gene product is inhibited, which develops inflammatory bowel disease when subjected to elevated chlorine concentrations, e.g. given chlorinated drinking water. Methods of screening for compounds useful for the treatment of inflammatory bowel disease, as well as methods to identify, for example, new targets for new compounds for the treatment of inflammatory bowel disease are also described.
    Type: Application
    Filed: February 9, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc
    Inventors: Katharine Helen Banner, Aleksandar Popovic
  • Publication number: 20040220253
    Abstract: A method for preparing particular pyrrole-carboxamides which selectively bind to GABAa receptors; which comprises reacting 1,3-cycloalkanediones with bromoethylacetate followed by reaction of the resulting product with an acid halide followed by reaction with an aromatic amine and finally with an amonium source at an elevated temperature.
    Type: Application
    Filed: June 3, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc.
    Inventor: John A. Ragan
  • Publication number: 20040220186
    Abstract: The invention provides compounds of Formula (I) 1
    Type: Application
    Filed: April 20, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc.
    Inventors: Andrew Simon Bell, Michael Paul DeNinno, Michael John Palmer, Michael Scott Visser
  • Publication number: 20040220274
    Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an anxiolytic agent or antidepressant.
    Type: Application
    Filed: May 28, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc.
    Inventor: Susan B. Sobolov-Jaynes
  • Publication number: 20040219512
    Abstract: The present invention relates to methods of screening candidate therapeutics for their ability to induce cataractogenesis by measuring the flux of ions through potassium ion channels.
    Type: Application
    Filed: April 28, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc
    Inventor: Christopher J. Somps
  • Publication number: 20040220184
    Abstract: Pharmaceutical compositions are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
    Type: Application
    Filed: May 21, 2004
    Publication date: November 4, 2004
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Jotham Wadsworth Coe, Steven Bradley Sands, Edmund Patrick Harrigan, Brian Thomas O'Neill, Eric Jacob Watsky
  • Publication number: 20040220224
    Abstract: The invention features a method of treating irritable bowel syndrome (IBS) by administering quarternary ammonium compounds of formulae I-V, described herein.
    Type: Application
    Filed: April 13, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc
    Inventors: Ivan Michael Richards, Karen Patrice Kolbasa
  • Publication number: 20040220229
    Abstract: The invention provides compounds of formula (I) 1
    Type: Application
    Filed: April 30, 2004
    Publication date: November 4, 2004
    Applicant: Pfizer Inc
    Inventors: Donald L. Bussolotti, Ronald B. Gammill
  • Publication number: 20040220177
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: December 11, 2003
    Publication date: November 4, 2004
    Applicant: Pfizer Inc
    Inventors: John Charles Kath, Michael Joseph Luzzio
  • Patent number: 6812002
    Abstract: The invention provides osteoactivin proteins and nucleic acid molecules that encode the same, as well as biologically functional expression vectors containing nucleic acid molecules encoding osteoactivin proteins, and antibodies specific for osteoactivin proteins. The invention also provides therapeutic and diagnostic compositions and methods for utilizing the proteins, antibodies, nucleic acids, and vectors of the invention, for example, to modulate bone formation.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: November 2, 2004
    Assignees: Pfizer Inc., Temple Univeristy
    Inventors: Steven N. Popoff, Fayez F. Safadi, Thomas A. Owen, Steven L. Smock
  • Patent number: 6812241
    Abstract: Compounds of formula (I) wherein the substituents are as defined herein, are antiparasitic agents.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: November 2, 2004
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb
  • Patent number: 6812236
    Abstract: There is provided a compound of formula I, wherein A, D, R1, R2, R3, X and n have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: November 2, 2004
    Assignee: Pfizer Inc.
    Inventors: Stephen Paul Gibson, Ivan Tommasini, David Morris Gethin, Richard Edward Armer
  • Patent number: 6812350
    Abstract: The present invention relates to a method of making novel dipeptidyl peptidase-IV (“DPP-IV’) inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: November 2, 2004
    Assignee: Pfizer Inc.
    Inventor: Bernard Hulin
  • Publication number: 20040214855
    Abstract: Compounds of Formula (I) and (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: April 12, 2004
    Publication date: October 28, 2004
    Applicant: Pfizer Inc
    Inventors: Philip A. Carpino, Robert L. Dow
  • Publication number: 20040214856
    Abstract: Compounds of Formula (I) and (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: April 12, 2004
    Publication date: October 28, 2004
    Applicant: Pfizer Inc
    Inventors: Philip A. Carpino, Robert L. Dow